Arca biopharma Completes Enrollment of Phase 2B Clinical Trial

Arca biopharma has completed enrollment for Genetic-AF, a phase 2B clinical trial evaluating Gencaro (bucindolol hydrochloride) as a potential genetically-targeted treatment for atrial fibrillation (AF). “We believe reaching our target enrollment in [Genetic-AF] represents a key clinical milestone for [Arca] and we look forward to reporting top-line data for the trial,” said Arca CEO Michael Bristow, “which we estimate should include approximately 50% more events than were available at the recently conducted interim analysis.” Arca said it expects to report top-line data late in Q1 of 2018.

Leave a Comment